Emdina, AnnaHermann, PeterVarges, DanielaNuhn, SabineGoebel, StefanBunck, TimothyMaass, FabianSchmitz, MatthiasLlorens, FrancKruse, NielsLingor, PaulMollenhauer, BritZerr, Inga2025-11-062025-11-062022-05-182075-4418https://hdl.handle.net/2445/224143Biomarkers are increasingly recognized as tools in the diagnosis and prognosis of neurodegenerative diseases. No fluid biomarker for Parkinson's disease (PD) has been established to date, but alpha-synuclein, a major component of Lewy bodies in PD and dementia with Lewy bodies (DLB), has become a promising candidate. Here, we investigated CSF oc-synuclein in patients with PD (n = 28), PDD (n = 8), and DLB (n = 5), applying an electrochemiluminescence immunoassay. Median values were non-significantly (p = 0.430) higher in patients with PDD and DLB (287 pg/mL) than in PD (236 pg/mL). A group of n = 36 primarily non-demented patients with PD and PDD was clinically followed for up to two years. A higher baseline oc-synuclein was associated with increases in Hoehn and Yahr classifications (p = 0.019) and Beck Depression Inventory scores (p < 0.001) as well as worse performance in Trail Making Test A (p = 0.017), Trail Making Test B (p = 0.043), and the Boston Naming Test (p = 0.002) at follow-up. Surprisingly, higher levels were associated with a better performance in semantic verbal fluency tests (p = 0.046). In summary, CSF oc-synuclein may be a potential prognostic marker for disease progression, affective symptoms, and executive cognitive function in PD. Larger-scaled studies have to validate these findings and the discordant results for single cognitive tests in this exploratory investigation.12 p.application/pdfengcc-by (c) Emdina, Anna et al., 2022http://creativecommons.org/licenses/by/3.0/es/Malalties del sistema nerviós centralMalaltia de ParkinsonTrastorns motorsCentral nervous system diseasesParkinson's diseaseMovement disordersinfo:eu-repo/semantics/article2025-11-05info:eu-repo/semantics/openAccess35626415